Formulation: A solid
Formal Name: N2-acetyl-L-lysyl-L-arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-3-(2-naphthalenyl)-D-alanyl-L-isoleucine, trifluoroacetate salt
Purity: ≥95%
Formula Markup: C57H81N13O12 • XCF3COOH
Formula Weight: 1140,3
Shelf life (days): 1460
Notes: R 715 is a bradykinin B1 receptor antagonist.{67457} It inhibits contractions induced by bradykinin (Item No. 37408) in isolated human umbilical cords, which express bradykinin B1 receptors (pA2 = 8.49). R 715 (200, 400, and 600 µg/kg) decreases the latency to tail withdrawal in the tail-flick test in a mouse model of diabetic neuropathy induced by streptozotocin (STZ; Item No. 13104).{67458} It reduces the incidence of hind limb weakness and paralysis, improves symmetrical gait, as well as decreases spinal inflammatory foci numbers, neuron demyelination, and lesion monocyte invasion, in a myelin oligodendrocyte glycoprotein (MOG) (35-55) (MOG35-55) antigen peptide-induced mouse model of experimental autoimmune encephalomyelitis (EAE) when administered at a dose of 1 mg/kg per day.{67459} R 715 (0.01 nmol/animal, i.c.v.) reduces mean arterial blood pressure and increases heart rate in spontaneously hypertensive rats.{67460}
English
Deutsch
